Animal Drug Compounding Market | Size | Analysis | Share | Outlook to 2032Posted by sandeep gade on November 30th, 2022 Animal drug compounding is the procedure of combining, mixing, or modifying ingredients to create a medication customized to the needs of animals, and these medications can be extremely useful in veterinary medicine. Growing demand for such customized medication has led the market to grow significantly in the past and reach a valuation of US$ 1.84 Bn in 2021. The market is projected to register 8.2% CAGR and top a valuation of US$ 4 Bn by 2031. Central nervous system inflammation is found to be the most common reason that causes neurological disorders in dogs and cats. High cost associated with branded animal drugs, especially for those employed in the treatment of neoplastic and immune-mediated diseases, is cited as one of the important factors by veterinarians leading to increasing number of compounded drug prescriptions. Also, the overall expenditure for animal medical care for many pet owners is completely out of pocket, and very limited animal species are covered under medical insurance policies. As such, a large number of veterinarians are prescribing compounded versions of approved branded drug. These include chlorambucil for lymphoma, and drugs for atopic dermatitis and fungal infection. Thus, high demand for CNS drugs will drive animal drug compounding market growth over the coming years. Key Takeaways from Market Study
“Lower availability of generic substitutes and increasing regulatory compliance are expected to offer market growth opportunities over the coming years," says an analyst of Persistence Market Research. Buy Full Report Now and Get Up to 20% Discount: https://www.persistencemarketresearch.com/checkout/12871 Like it? Share it!More by this author |